Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group

Open source

DOI
10.1016/s0140-6736(22)00163-5
Published
2022 Feb 12
Container
Lancet (London, England)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-22-00163-5,
  title = {Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.},
  author = {RECOVERY Collaborative Group},
  year = {2022},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(22)00163-5},
  url = {https://doi.org/10.1016/s0140-6736(22)00163-5}
}

RIS

TY  - JOUR
TI  - Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
AU  - RECOVERY Collaborative Group
PY  - 2022
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(22)00163-5
UR  - https://doi.org/10.1016/s0140-6736(22)00163-5
ER  - 

APA

Group, R. C. (2022). Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(22)00163-5

Source records